Skip to main content

BRIEF RESEARCH REPORT article

Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1347306
This article is part of the Research Topic Antimicrobial Resistance and Modern Therapeutics Approaches View all 10 articles

First case report of a vertebral osteomyelitis caused by carbapenemresistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion

Provisionally accepted
Paul LAFFONT Paul LAFFONT 1*Tayma NACIRI Tayma NACIRI 1Alix PANTEL Alix PANTEL 2aurelie MARTIN aurelie MARTIN 1Anne-Sophie PRUVOT-OCCEAN Anne-Sophie PRUVOT-OCCEAN 2vincent HAIGNERE vincent HAIGNERE 2Paul LOUBET Paul LOUBET 1,3Albert SOTTO Albert SOTTO 1,3Romaric LARCHER Romaric LARCHER 1,4
  • 1 Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nïmes, France
  • 2 Centre Hospitalier Universitaire de Nîmes, Nîmes, Languedoc-Roussillon, France
  • 3 INSERM U1047 Virulence Bactérienne et Maladies Infectieuses, Nîmes, Languedoc-Roussillon, France
  • 4 INSERM U1046 Physiologie et Médecine Expérimentale du Coeur et des Muscles, Montpellier, Languedoc-Roussillon, France

The final, formatted version of the article will be published soon.

    Introduction: Bone and joint infections (BJIs) caused by multidrug-resistant bacteria are becoming more frequent. However, data on the use of novel β-lactam/β-lactamase inhibitors, such as imipenem/cilastatin/relebactam (I-R) and meropenem/vaborbactam (MVB), to treat BJIs is lacking. Furthermore, prolonged infusions of these β-lactams should theoretically optimize pharmacokinetic/pharmacodynamics target in these indications, but there are currently no reports on this type of infusions, especially in the setting of BJI. a mis en forme : Anglais (Royaume-Uni) a mis en forme : Police :Italique, Anglais (Royaume-Uni) a mis en forme : Anglais (Royaume-Uni) a mis en forme : Français (France) a mis en forme : Anglais (Royaume-Uni) a mis en forme : Anglais (Royaume-Uni) a mis en forme : Français (France) a mis en forme : Anglais (Royaume-Uni) a mis en forme : Français (France) a mis en forme : Anglais (Royaume-Uni) Case presentation: We report a case of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae successfully treated with extended-infusion of I-R (1.25 g q6h over 2h), then with continuous infusion of MVB (2g q4h as over 4h). Therapeutic drug monitoring confirmed that extended-infusion of I-R and continuous infusion of MVB achieved serum concentrations up to 12 mg/L of imipenem and 19 mg/L of meropenem, respectively.The favorablefavourable outcome of this patient treated for a vertebral osteomyelitis caused by carbapenem-resistant E. . cloacae suggest that extended-and continuous infusions of I-R and MVB, are promising regimens for treatment of BJIs caused by carbapenem-resistant Enterobacterales.

    Keywords: Bone and joint infection, Vertebral osteomyelitis, Meropenem/Vaborbactam, Continuous infusion, imipenem/cilastatin/relebactam, Extended infusion, Therapeutic drug monitoring

    Received: 30 Nov 2023; Accepted: 18 Sep 2024.

    Copyright: © 2024 LAFFONT, NACIRI, PANTEL, MARTIN, PRUVOT-OCCEAN, HAIGNERE, LOUBET, SOTTO and LARCHER. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Paul LAFFONT, Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nïmes, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.